Guardant Health, Inc. (NASDAQ:GH) Receives Average Recommendation of “Buy” from Analysts

Guardant Health, Inc. (NASDAQ:GH) has been given an average recommendation of “Buy” by the sixteen research firms that are presently covering the company, MarketBeat.com reports. Sixteen equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $42.63.

Several brokerages have issued reports on GH. Sanford C. Bernstein dropped their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Leerink Partners dropped their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Guggenheim reaffirmed a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Barclays began coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th.

Insider Transactions at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,548 shares of company stock worth $179,782 in the last quarter. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently made changes to their positions in GH. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Guardant Health by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after acquiring an additional 796 shares during the period. Fiduciary Alliance LLC grew its holdings in Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock valued at $363,000 after purchasing an additional 836 shares during the last quarter. R Squared Ltd purchased a new position in shares of Guardant Health in the fourth quarter valued at $26,000. Van ECK Associates Corp raised its stake in shares of Guardant Health by 47.4% during the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock worth $88,000 after buying an additional 929 shares during the last quarter. Finally, JNBA Financial Advisors purchased a new stake in shares of Guardant Health in the 3rd quarter worth about $26,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

GH opened at $47.57 on Tuesday. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The firm has a market capitalization of $5.88 billion, a P/E ratio of -11.22 and a beta of 1.28. The company’s 50-day moving average is $37.21 and its 200 day moving average is $30.24.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.73) earnings per share. On average, equities research analysts expect that Guardant Health will post -3.43 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.